REGENERON PHARMACEUTICALS, INC. Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0000872589
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2026 · 3 positions · Total reported value $177.22M · Top-10 concentration 100.0% · Updated 2026-10-24
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
Turnover: 0.0% · 0 new · 0 cut · 0 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
In its Q2 2026 13F filing, REGENERON PHARMACEUTICALS, INC. disclosed 3 equity positions with a combined reported value of $177.22M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / Buy & Hold.
The largest disclosed positions as of Q2 2026 were PBLS ($114.04M), NTLA ($62.65M), ACET ($522.82K). By sector, the heaviest allocations are Health Care 100.0%.
Versus the prior quarter, REGENERON PHARMACEUTICALS, INC. opened 0 new positions, trimmed 0 and fully exited 0, a turnover rate of 0.0% of positions. The portfolio's overlap with the prior quarter was 67% of names.
The largest new positions opened in Q2 2026 were PBLS ($114.04M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2026)
- PBLS Parabilis Medicines, Inc. · $114.04M
Fully Exited (vs previous quarter)
No tracked position was fully exited this quarter.
Insider Transactions (Form 4)
Latest REGENERON PHARMACEUTICALS, INC. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Regeneron Pharmaceuticals files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 3 positions worth $177.22M in total. HoldingsHub carries 7 quarters of its filings (Q4 2024–Q2 2026).
Portfolio Structure
- 3 positions · $177.22M reported value (Q2 2026)
- Top 10 holdings = 100.0% of reported value
- Largest position: PBLS (PARABILIS MEDICINES INC) at 64.4%
- Average position size: $59.07M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 1 new
- 2 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
Sector Allocation
FAQ
What did REGENERON PHARMACEUTICALS, INC. buy in 2026-Q2?
In its 2026-Q2 13F filing, REGENERON PHARMACEUTICALS, INC. reported 3 equity positions worth $177.22M in aggregate; its largest disclosed positions were PBLS ($114.04M), NTLA ($62.65M), ACET ($522.82K).
How large is REGENERON PHARMACEUTICALS, INC.'s portfolio?
REGENERON PHARMACEUTICALS, INC. reported $177.22M of long equity holdings across 3 positions as of 2026-Q2. Top-10 holdings account for 100.0% of reported value.
What is REGENERON PHARMACEUTICALS, INC.'s investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / Buy & Hold, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.